bolt biotherapeutics stock forecast

Bolt Biotherapeutics Presents Preliminary Results from Phase 1/2 Trial of Lead HER2-targeting Boltbody™ ISAC BDC-1001 at ASCO 2021. Bolt Biotherapeutics … Last 30 Days. ... Cash Markets Overview Corn Indexes Soybean Indexes Wheat Indexes Metal Indexes Energies Indexes Yield Forecast … Bolt’s lead candidate, BDC-1001, is a Boltbody ISAC comprised of a HER2-targeting biosimilar of trastuzumab conjugated to one of Bolt’s proprietary TLR7/8 agonists for the treatment of patients with HER2-expressing solid tumors. Bolt is also advancing additional Boltbody ISAC product candidates targeting CEA and PD-L1. View the latest Bolt Biotherapeutics Inc. (BOLT) stock price, news, historical charts, analyst ratings and financial information from WSJ. DATA AS OF May 21, 2021. The … Bolt Biotherapeutics … The average 12-month stock price forecast for BOLT is 41.00, which is an increase of 49.42% from the latest price. BOLT: Get the latest Bolt Biotherapeutics stock price and detailed information including BOLT news, historical charts and realtime prices. Add to Portfolio. Bolt… Bolt Biotherapeutics stock price prediction is an act of determining the future value of Bolt Biotherapeutics shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation. The average price target is $35.00 with a high forecast of $37.00 and a low forecast of $33.00. Stock analysis for Bolt Biotherapeutics Inc (BOLT:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Stocks under 20 dollars, stocks for 20 USD. Bolt Biotherapeutics, Inc. (NASDAQ:BOLT)’s stock price traded down 4.1% during mid-day trading on Monday after SVB Leerink lowered their price target on the stock from $37.00 to $33.00. UNCH. View Bolt Biotherapeutics, Inc. BOLT investment & stock information. The price target was changed from $37.00 to $33.00. Please note that any opinions, estimates or forecasts regarding Bolt Biotherapeutics's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Bolt Biotherapeutics … $18.75. Poster showcases positive preliminary data from first 20 … As of 2021 June 17, Thursday current price of ASXC stock is 3.420$ and our data indicates that the asset price has been in a downtrend for the past 1 year (or since its inception).. Asensus Surgical stock … Bolt Biotherapeutics Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. SVB Leerink currently has an outperform rating on the stock. Bolt Biotherapeutics, Inc. Common Stock (BOLT) Nasdaq Listed. REDWOOD CITY, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage immuno-oncology company, announced today the closing of its initial public offering of 13,225,000 shares of its common stock… The consensus among 4 Wall Street analysts covering ( NASDAQ : BOLT ) stock is to Strong Buy BOLT stock. Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights – Upsized IPO in February 2021 raised $264.5 million in gross proceeds plus Series C raised $93.5 million for a total of $358 million in recent fundraising – As of 2021 June 01, Tuesday current price of BUZZ stock is 0.080$ and our data indicates that the asset price has been in a downtrend for the past 1 year (or since its inception).. Pharmadrug stock … Fed brightens forecast for economic recovery, with more officials warming up to rate hike. What this means: InvestorsObserver gives Bolt Biotherapeutics Inc (BOLT) an overall rank of 36, which is below average. Mar 31, 2021. During the day the stock fluctuated 3.30% from a day low at $15.45 to a day high of $15.96. Nasdaq 100. Bolt Biotherapeutics … According to present data Bolt Biotherapeutics's BOLT shares and potentially its market environment have been in bearish cycle last 12 months (if exists). Find the latest Bolt Biotherapeutics, Inc. (BOLT) stock quote, history, news and other vital information to help you with your stock trading and investing. DATA AS OF May 21, 2021. We use big data and artificial intelligence to forecast the stock price of Bolt Biotherapeutics Inc Ordinary Shares - BOLT. Date Range. Data is currently not available. Get the latest Bolt Biotherapeutics, Inc. BOLT detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Data is currently not available. BOLT Consensus Estimates Our Bolt Biotherapeutics consensus estimates page is based on consensus analyst forecast, covering public companies earnings per share and revenue. Bolt Biotherapeutics, Inc., a clinical-stage immuno-oncology company, engages in the discovery, development, and commercialization of pharmaceutical products. Bolt Biotherapeutics, Inc. is a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Bolt Biotherapeutics, Inc. (BOLT), a clinical-stage immuno-oncology company, announced today the closing of its initial public offering of 13,225,000 shares of its common stock, inclusive of the full exercise by the underwriters of their option to purchase 1,725,000 shares of common stock… Bolt Biotherapeutics, Inc., a clinical-stage immuno-oncology company, engages in the discovery, development, and commercialization of pharmaceutical products. ... Bolt Biotherapeutics, Inc. (BOLT) stock forecast and price target. Get the hottest stocks to trade every day before the market opens 100% free. Based on 2 Wall Street analysts offering 12 month price targets for Bolt Biotherapeutics in the last 3 months. Showing 1,401-1,500 of 14,842 items. stock was originally listed at a price of $32.60 in Feb 8, 2021. Bolt Biotherapeutics Reports First Quarter 2021 Financial Results and Provides Business Highlights. UNCH. Bolt Biotherapeutics stock price prediction is an act of determining the future value of Bolt Biotherapeutics shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation.The successful prediction of Bolt Biotherapeutics stock … Bolt Biotherapeutics, founded by Stanford immuno-oncology veteran Edgar Engleman, is developing new class of cancer drugs called immune stimulating antibody conjugates. ... Stock Market Ideas. Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of … Accident & Health Insurance Accommodation and Food Services … Latest Release. BOLT Earnings. and has now fallen 3 days in a row. SVB Leerink currently has an outperform rating on the stock. A high-level overview of Bolt Biotherapeutics, Inc. (BOLT) stock. In depth view into BOLT (Bolt Biotherapeutics) stock including the latest price, news, dividend history, earnings information and financials. REDWOOD CITY, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage immuno-oncology company, announced today the closing of its initial public offering of 13,225,000 shares of its common stock… Bolt Biotherapeutics Inc (. BOLT. ) Company profile. Customizable interactive chart for Bolt Biotherapeutics Inc with latest real-time price quote, charts, latest news, technical analysis and opinions. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. View more. Bolt Biotherapeutics, Inc. Common Stock (BOLT) Nasdaq Listed. About the Asensus Surgical Inc stock forecast. Our stock price predictions cover a … Click to view NSQ:BOLT's StockReport About Bolt Biotherapeutics, Inc. Bolt Biotherapeutics… Company profile. Bolt Biotherapeutics, Inc. Stock Forecast NASDAQ:BOLT Price Target and Analyst Ratings. Bolt Biotherapeutics, Inc. Common Stock (BOLT) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. January 5, 2021. Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of … The average price target is $41.00, with a high forecast of $45.00 and a low forecast of $37.00. Bolt Biotherapeutics … Backed by fresh data from … View BOLT's stock price, price target, earnings, forecast, insider trades, and news at MarketBeat. A rank of 36 means that 64% of stocks appear more favorable to our system. $18.75. The forecast for the further price development, based on current price information, is -1.85% (time horizon: 1 day) and results in a price target of $17.99. Chart fundamental metrics like Market Cap, Fair Value, EV/EBITDA, P/E Ratio, Forecasts, Stock Price, Debt / Total Capital and more. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. The Company is developing tumor-targeted therapies that leverage the power of the innate and … Most Recent Rating. On average, they anticipate Bolt Biotherapeutics' stock price to reach $40.00 in the next year. ... Stock Market Ideas. Bolt Biotherapeutics, Inc is a clinical-stage immuno-oncology company. Stockopedia rates Bolt Biotherapeutics Inc as a Speculative Sucker Stock . Technical stocks chart with latest price quote for Bolt Biotherapeutics Inc, with technical analysis, latest news, and opinions. 3 brokers rate it as a 'Strong Buy'. The last closing price of the Bolt Biotherapeutics, Inc share was $18.33 and has changed by -4.48% since the penultimate trading day. Add to Watchlist. Date Range. 4 equities research analysts have issued 12-month target prices for Bolt Biotherapeutics' stock. Is Bolt Biotherapeutics Stock a good buy in 2021, according to Wall Street analysts? The Bolt Biotherapeutics, Inc. stock price fell by -0.94% on the last day (Friday, 18th Jun 2021) from $16.03 to $15.88. Bolt Biotherapeutics' IPO stock is set to begin trading on Feb. 5. View the latest BOLT stock quote and chart on MSN Money. Nasdaq 100. The price has fallen in 7 of the last 10 days and is down by -4.62% for this period. Completed upsized Initial Public Offering in February 2021 – In February 2021, Bolt completed its Initial Public Offering (IPO) of 13,225,000 shares of common stock… About the VanEck Vectors ETF Trust – VanEck Vectors Social Sentiment ETF stock forecast. BOLT BIOTHERAPEUTICS, INC. company earnings calendar and analyst expectations - Upcoming and past events | Nasdaq: BOLT | Nasdaq ... Forecast Spread: 0,22: 0,23 0,26-10%: Operating income (EBITDA) M $ Released Forecast Spread-47,2-42,5 ... Stock … View charts for Bolt Biotherapeutics, Inc. (NASDAQGS:BOLT). The company develops BDC-1001, a … Bolt is utilizing its Boltbody™ platform to create immune-stimulating antibody conjugates (ISACs), such as BDC-1001, that invoke this mechanism and provided complete tumor regression in preclinical tumor models. “In murine models we have seen efficacy in a variety of tumors that are immunologically cold and well-established. Add to Portfolio. BOLT: Bolt Biotherapeutics, Inc. - Price and Consensus Chart. Past 12 Months 12 Months Forecast $15 $20.8 $26.5 $32.3 $38 Oct Bolt Biotherapeutics, Inc is a clinical-stage immuno-oncology company. Bolt Biotherapeutics, based in the San Francisco Bay Area, is a private clinical-stage biotechnology company developing Boltbody™ Immune-Stimulating Antibody Conjugates (ISACs), a … If you had invested in Bolt Biotherapeutics stock at $32.60, your return over the last 0 years would have been -48.93%. Bolt Biotherapeutics, Inc. (NASDAQ:BOLT)’s share price reached a new 52-week low during trading on Tuesday after SVB Leerink lowered their price target on the stock from $37.00 to $33.00. Out of 4 analysts, 3 ( 75% ) are recommending BOLT as a Strong Buy, 1 ( 25% ) are recommending BOLT as a Buy, 0 ( 0% ) are recommending BOLT as a Hold, 0 ( 0% ) are recommending BOLT as a Sell, and 0 ( 0% ) are recommending BOLT … Bolt Biotherapeutics, Inc. is a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. ... Bolt Biotherapeutics, Inc. (BOLT) stock forecast and price target. Bolt Biotherapeutics, based in the San Francisco Bay Area, is a private clinical-stage biotechnology company developing Boltbody™ Immune-stimulating Antibody Conjugates (ISACs), a … This price target is based on 4 analysts offering 12 month price targets for Bolt Biotherapeutics in the last 3 months. EPS / Forecast. In the most recent purchasing and selling session, Viant Technology Inc. (DSP)’s share price … Click here now. ... Cash Markets Overview Corn Indexes Soybean Indexes Wheat Indexes Metal Indexes Energies Indexes Yield Forecast … SVB Leerink is very positive about BOLT and gave it a "Outperform" rating on May 24, 2021. Analyzing Bolt Biotherapeutics (CNSX:BOLT) stock? Fed brightens forecast for economic recovery, with more officials warming up to rate hike. Add to Watchlist. Get the latest Price and Consensus Chart for Bolt Biotherapeutics, Inc. from Zacks Investment Research Bolt Biotherapeutics is followed by the analysts listed above. The company sold 11.5 million shares at $20 each, raising $230 million. The successful prediction of Bolt Biotherapeutics stock future price could yield a significant profit. Their forecasts range from $33.00 to $45.00. Loss from Operations – Loss from operations was $24.5 million for the quarter ended March 31, 2021 compared to $8.6 million for the same quarter in 2020. Find real-time BOLT - Bolt Biotherapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. SVB Leerink currently has an outperform rating on the stock. REDWOOD CITY, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage immuno-oncology company, announced today the pricing of its upsized initial public offering of 11,500,000 shares of common stock at a price to the public of $20.00 per share. Recent Business Highlights and Anticipated Milestones. Wall Street Stock Market & Finance report, prediction for the future: You'll find the Bolt Biotherapeutics share forecasts, stock quote and buy / sell signals below. The average price target represents a 64.13% upside from the last price of $24.98. The Company is developing tumor-targeted therapies that leverage the power of the innate and … Dive deeper with interactive charts and top stories of BOLT BIOTHERAPEUTICS, INC.. Bolt Biotherapeutics, Inc. (NASDAQ:BOLT)’s share price reached a new 52-week low on Tuesday after SVB Leerink lowered their price target on the stock from $37.00 to $33.00. The latest earnings per stock, revenues and financial reports for Bolt Biotherapeutics (BOLT). Bolt Biotherapeutics. This suggests a possible upside of … Bolt Biotherapeutics, Inc. was incorporated in 2015 and is … The average price target represents a 118.34% from the last price of $16.03. Company profile page for Bolt Biotherapeutics Inc including stock price, company news, press releases, executives, board members, and contact information